Pharma News, 2025

The Food and Drug Administration on Tuesday approved a new treatment for a rare skin condition, teeing up a commercial battle between two cell and gene therapy developers.

CAMBRIDGE, Mass. - Nuvalent, Inc., a clinical-stage biopharmaceutical company valued at $5.4 billion

Amgen has announced a significant expansion of a manufacturing facility in the US state of Ohio, with an investment of $900m.

AbbVie  recently secured FDA approval for RINVOQ (Upadacitinib) to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company&...

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Pfizer’s sasanlimab improves event-free survival in phase 3 bladder cancer trial

The European Commission (EC) has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).

Gilead Sciences’ stock is up 12% this year, topping a 1% gain for the NYSE Arca Pharmaceutical Index.  Chief Executives don’t usually brag about paying high tax rates.

Ipsen’s elafibranor (sold under the brand name Iqirvo) has shown promise as a treatment for primary sclerosing cholangitis (PSC),

Eli Lilly's New Weight Loss Drug May Have the Worst Name in Pharmaceutical Histrory

Early treatment with Ocrevus (ocrelizumab) may help protect the cerebellum, a region of the brain that plays a key role in motor coordination

Thermo Fisher Scientific to invest $2bn into US manufacturing capabilities